← Back to Search

Corticosteroid

Elotuzumab for Multiple Myeloma

Phase 2

Waitlist Available

Led By Irene Ghobrial, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will help researchers understand how well a combination of elotuzumab, lenalidomide, and dexamethasone works in treating people with smoldering multiple myeloma.

Eligible Conditions

Myeloma
Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percent of Patients Who Are Progression Free at 2 Years

Secondary outcome measures

Objective Response Percent

Overall Survival

Time to Progression

Trial Design

2Treatment groups

Experimental Treatment

Group I: Elo / Len / DexExperimental Treatment3 Interventions

•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8 Other Name: HuLuc63 •Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24 Other Name: REVLIMID •Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8 Other Name: Decadron

Group II: Elo / LenExperimental Treatment2 Interventions

•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8 Other Name: HuLuc63 •Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24 Other Name: REVLIMID

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Elotuzumab

2016

Completed Phase 3

~800

Dexamethasone

2007

Completed Phase 4

~2590

Lenalidomide

2005

Completed Phase 3

~1480

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,078 Previous Clinical Trials

340,821 Total Patients Enrolled

51 Trials studying Multiple Myeloma

34,271 Patients Enrolled for Multiple Myeloma

The Leukemia and Lymphoma SocietyOTHER

82 Previous Clinical Trials

17,080 Total Patients Enrolled

12 Trials studying Multiple Myeloma

2,174 Patients Enrolled for Multiple Myeloma

Multiple Myeloma Research ConsortiumNETWORK

20 Previous Clinical Trials

1,307 Total Patients Enrolled

19 Trials studying Multiple Myeloma

1,254 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Elotuzumab been validated by the Food and Drug Administration?

"Elotuzumab is presently in the second phase of clinical trials and thus has been assigned a safety rating of 2, since there exists some evidence for its security but no assessment of efficacy."

Answered by AI

What is the principal application of Elotuzumab?

"Elotuzumab is a popular remedy for ophthalmia, sympathetic and can also prove effective against branch retinal vein occlusion, macular edema, or patients with experience two or more prior systemic chemotherapy regimens."

Answered by AI

Are there still openings in this research trial?

"This research endeavor is not currently accepting applicants. It was initially made available on December 11, 2014 and last modified November 1 2021. For those seeking alternative studies, 808 trials for smoldering multiple myeloma are presently recruiting participants in addition to 701 clinical tests utilizing elotuzumab."

Answered by AI

Can you provide a summary of the prior experiments that have employed Elotuzumab?

"As of now, there are 701 active investigational studies surrounding Elotuzumab with 166 in the final stage. The majority of these trials take place at one location in Mishawaka, Indiana; however, 25504 sites worldwide have begun running clinical tests on this drug."

Answered by AI

How many health care facilities are actively conducting this clinical trial?

"Currently, 9 sites are partaking in this trial. These locations consist of Hartford, Baltimore and Brewer among other cities. To reduce any burdens associated with travel it is beneficial to choose the nearest option if you decide to participate in the study."

Answered by AI

What is the total enrollment count for this research effort?

"This investigation is no longer active, having been first posted on December 11th 2014 and most recently updated on November 1st 2021. However, there are still 808 studies actively recruiting candidates with smoldering multiple myeloma and 701 trials for Elotuzumab looking for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Irene Ghobrial, MD 2014. "E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02279394.